

Adaptimmune Therapeutics PLC  
Form 6-K  
November 24, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of November, 2015

Commission File Number: 001-37368

---

**ADAPTIMMUNE THERAPEUTICS PLC**

(Translation of registrant's name into English)

---

**101 Park Drive, Milton Park**  
**Abingdon, Oxfordshire OX14 4RY**  
**United Kingdom**

## Edgar Filing: Adaptimmune Therapeutics PLC - Form 6-K

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒

Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ☐

No ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ☐

No ☐

---

**Other Events**

On November 24, 2015, Adaptimmune Therapeutics plc (the Company) issued a press release announcing that it has initiated a study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with Stage IIIb or Stage IV non-small cell lung cancer (NSCLC), the most common type of lung cancer, representing approximately 85 percent of lung cancers. The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

**Exhibits**

99.1 Press release dated November 24, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Adaptimmune Therapeutics plc**

By:	/s/ Margaret Henry
Name:	Margaret Henry
Title:	Corporate Secretary

Date: November 24, 2015